BioMarin gears up for two 'transformational' launches, Voxzogo and Roctavian: CEO

While BioMarin bested expectations with its second-quarter performance, the biotech is zeroed in on its two next-gen medicines. And no wonder: Those drugs, Voxogo and Roctavian, could completely transform the company, CEO J.J. Bienaimé said.

BioMarin’s Voxzogo to treat achondroplasia and its hemophilia A gene therapy Roctavian are up for potential approvals this year and next year, respectively—and analysts are keeping close tabs.